GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Current Accrued Expense

TheraCryf (LSE:TCF) Current Accrued Expense : £0.00 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Current Accrued Expense?

TheraCryf's Current Accrued Expense for the quarter that ended in Mar. 2024 was £0.00 Mil.


TheraCryf Current Accrued Expense Historical Data

The historical data trend for TheraCryf's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Current Accrued Expense Chart

TheraCryf Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TheraCryf Semi-Annual Data
Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TheraCryf Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


TheraCryf Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of TheraCryf's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (LSE:TCF) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.